Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Diagnostics of Alzheimer's disease (AD) commonly employ the use of fluorescent thioflavin derivatives having affinity for the amyloid-β (Aβ) proteins associated with AD progression. However, thioflavin probes have limitations in their diagnostic capabilities arising from a number of undesireable qualities, including poor photostability, weak emission intensity, and high emission overlap with the backgound tissue autofluorescence. To overcome such limitations, we have developed nanoformulated probes consisting of a red-emitting fluorescent quantum dot (QD) core encapsulated in a PEGylated shell with benzotriazole (BTA) targeting molecules on the surface (QD-PEG-BTA). The combination of strong red fluorescence, multivalent binding, and decreased backgound signal and nonspecific binding provided the ability of the QD-PEG-BTA probes to achieve detection sensitivites 4 orders of magnitude greater than those of conventional thioflavin derivatives. This study opens the door for the use of QDs in AD detection applications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.bioconjchem.6b00019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Measuring alignment between the ADRC UDS data elements, FDA, and EHR data standards.
Alzheimers Dement
September 2025
Department of Population Health Sciences, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Introduction: We compared and measured alignment between the Health Level Seven (HL7) Fast Healthcare Interoperability Resources (FHIR) standard used by electronic health records (EHRs), the Clinical Data Interchange Standards Consortium (CDISC) standards used by industry, and the Uniform Data Set (UDS) used by the Alzheimer's Disease Research Centers (ADRCs).
Methods: The ADRC UDS, consisting of 5959 data elements across eleven packets, was mapped to FHIR and CDISC standards by two independent mappers, with discrepancies adjudicated by experts.
Results: Forty-five percent of the 5959 UDS data elements mapped to the FHIR standard, indicating possible electronic obtainment from EHRs.
Retinal biomarkers in cognitive impairment and dementia: Structural, functional, and molecular insights.
Alzheimers Dement
September 2025
Department of Neurology, Beijing TianTan Hospital, Capital Medical University, Beijing, China.
Cognitive impairment and dementia, including Alzheimer's disease (AD), pose a global health crisis, necessitating non-invasive biomarkers for early detection. This review highlights the retina, an accessible extension of the central nervous system (CNS), as a window to cerebral pathology through structural, functional, and molecular alterations. By synthesizing interdisciplinary evidence, we identify retinal biomarkers as promising tools for early diagnosis and risk stratification.
View Article and Find Full Text PDFAge-related amyloid beta dynamics modeled with the generalized additive model for location, scale, and shape (GAMLSS) across diverse populations: Cross-sectional trajectories and longitudinal validation.
Alzheimers Dement
September 2025
Alzheimer's Disease Convergence Research Center, Samsung Medical Center, Seoul, South Korea.
Introduction: We developed and validated age-related amyloid beta (Aβ) positron emission tomography (PET) trajectories using a statistical model in cognitively unimpaired (CU) individuals.
Methods: We analyzed 849 CU Korean and 521 CU non-Hispanic White (NHW) participants after propensity score matching. Aβ PET trajectories were modeled using the generalized additive model for location, scale, and shape (GAMLSS) based on baseline data and validated with longitudinal data.
Plants, Pills, and the Brain: Exploring Phytochemicals and Neurological Medicines.
Int J Plant Anim Environ Sci
August 2025
Department of Translational Research, College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona, CA 91766, USA.
Neurological disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, spinal cord injuries, and traumatic brain injuries, represent substantial global health challenges due to their chronic and often progressive nature. While allopathic medicine offers a range of pharmacological interventions aimed at managing symptoms and mitigating disease progression, it is accompanied by limitations, including adverse side effects, the development of drug resistance, and incomplete efficacy. In parallel, phytochemicals-bioactive compounds derived from plants-are receiving increased attention for their potential neuroprotective, antioxidant, and anti-inflammatory properties.
View Article and Find Full Text PDFPreclinical dementia rating scores are associated with plasma phosphorylated tau-217.
Alzheimers Dement (Amst)
September 2025
Introduction: Simple screening tools are critical for assessing Alzheimer's disease (AD)-related pre-dementia changes. This study investigated longitudinal scores from the Quick Dementia Rating System (QDRS), a brief study partner-reported measure, in relation to baseline levels of the AD biomarker plasma pTau217 in individuals unimpaired at baseline.
Methods: Data from the Wisconsin Registry for Alzheimer's Prevention (N = 639) were used to examine whether baseline plasma pTau217 (ALZpath assay on Quanterix platform) modified QDRS or Preclinical Alzheimer's Cognitive Composite (PACC3) trajectories (mixed-effects models; time = age).